Clinical Trials Browser

Phase 2 × ensartinib × Thoracic × Clear all

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Phase 2 Active not recruiting

10 enrolled 17 charts

Lung Neoplasms

NCT07235306 2025-11-19

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06779539 2025-01-17

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780839 2025-01-17

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05491811 2024-09-19

EAGLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05186506 2022-01-11

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05178511 2022-01-05

ERSGATR

Phase 2 Unknown

The Diagnosis Was ALK Positive NSCLC

NCT04415320 2020-06-04

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung